Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 10 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Risk of colorectal high-grade dysplasia and cancer in IBD

A prospective study in the latest issue of Gastroenterology investigates the risk of colorectal high-grade dysplasia and cancer in patients with IBD.

News image

There is an unclear risk of colonic high-grade dysplasia and colorectal cancer among patients with inflammatory bowel disease treated with immunosuppressants.

Dr Laurent Beaugerie and colleagues analyzed data on colorectal cancer development among patients with inflamatory bowel disease enrolled in the observational cohort Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales En France.

The research team followed and collected data from 19,486 patients with inflamatory bowel disease enrolled in Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales En France from 2004 to 2005, and followed them until 2007.

When the study began, 2841 patients were characterized as having long-standing extensive colitis.

Early lesions high-grade dysplasia and colorectal cancer were defined as those diagnosed within 10 years after diagnosis of inflammatory bowel disease.

The standardized incidence ratios of colorectal cancer were 2.2 for all IBD patients
Gastroenterology

The researchers evaluated 37 patients that developed colorectal cancer during the follow-up period, and 20 developed colorectal higher-grade dysplasia.

The standardized incidence ratios of colorectal cancer were 2.2 for all inflammatory bowel disease patients, 7.0 for patients with long-standing extensive colitis, and 1.1 for patients without long-standing extensive colitis.

Among patients with long-standing extensive colitis, the multivariate adjusted hazard ratio for colorectal high-grade dysplasia and cancer was 0.28 for those who received thiopurines compared with those who never received thiopurine therapy.

The team observed that 22 patients developed early lesions.

The research team noted that 7 of these were related to inflammatory bowel disease, based on histologic analysis.

Dr Beaugerie's team comments, "Patients with IBD and long-standing extensive colitis are at increased risk for colorectal cancer, although the risk is lower among patients receiving thiopurine therapy."

"Patients without long-standing extensive colitis have a risk for colorectal cancer similar to that of the general population, but they can develop inflammatory bowel disease-related lesions within 10 years after diagnosis of inflamatory bowel disease."

Gastroenterol 2013: 145(1): 166-175
18 July 2013

Go to top of page Email this page Email this page to a colleague

 09 December 2016 
Use of GI alarm features for colorectal cancer diagnosis
 09 December 2016 
Emergency department use by IBD patients
 09 December 2016 
PPI regimens for upper GI bleeds
 08 December 2016 
Preterm birth in women with IBD
 08 December 2016 
Precision medicine in IBD
 08 December 2016 
Intestinal tuberculosis vs Crohn's disease
 07 December 2016 
Iron deficiency in ulcerative colitis
 07 December 2016 
IBD source of information and patient education
 07 December 2016 
End-of-rotation resident transition and in-hospital mortality
 06 December 2016 
Anti-TNF therapy for IBD
 06 December 2016 
Crohn's disease and thyroid cancer risk
 06 December 2016 
IBD Disability Index in restorative proctocolectomy
 05 December 2016 
Reducing hospitalization in IBD
 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Quality assurance standards for colonoscopy
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 21 November 2016 
Financial incentives and colorectal cancer screening
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Liver-related specialty care in patients with Hep C
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Contraceptives and ulcerative colitis
 15 November 2016 
Physician perspectives on Hep C management
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us